Saiama Waqar

Medicine & Life Sciences

1. Non-Small Cell Lung Carcinoma 100%
2. Small Cell Lung Carcinoma 40%
3. Lung Neoplasms 37%
4. Neoplasms 28%
5. Survival 22%
6. Drug Therapy 21%
7. Circulating Tumor DNA 21%
8. durvalumab 20%
9. Radiotherapy 17%
10. temsirolimus 17%
11. Platinum 17%
12. Therapeutics 15%
13. Squamous Cell Neoplasms 15%
14. Anaplastic Lymphoma Kinase 12%
15. atezolizumab 12%
16. Adjuvant Chemotherapy 12%
17. rovalpituzumab tesirine 10%
18. ensartinib 10%
19. Neoplasm Metastasis 10%
20. Etoposide 10%
21. Pemetrexed 10%
22. Confidence Intervals 9%
23. Mutation 9%
24. Medical Oncology 9%
25. Thorax 9%
26. Adenocarcinoma of Lung 9%
27. Maximum Tolerated Dose 8%
28. Carboplatin 8%
29. MP470 8%
30. Immunotherapy 8%
31. veliparib 7%
32. RRx-001 7%
33. TOR Serine-Threonine Kinases 7%
34. Progression-Free Survival 7%
35. Human Influenza 7%
36. MLN 8237 6%
37. Neuroendocrine Tumors 6%
38. Epidemiology 6%
39. 130-nm albumin-bound paclitaxel 6%
40. Nausea 6%
41. ramucirumab 6%
42. Vaccination 6%
43. palbociclib 6%
44. carfilzomib 6%
45. INCB018424 6%
46. Brain 5%
47. High-Throughput Nucleotide Sequencing 5%
48. olaparib 5%
49. Malignant Pleural Effusion 5%